Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | PPIB | P23284 | 1/20 | 0.37 |
| ▸ | PPIA | P62937 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911357 | 0.82 | HTR2A (0.51) | HTR2AKDR | |
| SCHEMBL4909184 | 0.81 | HTR2A (0.58) | HTR2ASCN5AKDR | |
| SCHEMBL4901511 | 0.81 | HTR2C (0.44) | HTR2ALRRK2TTK | |
| SCHEMBL4909199 | 0.78 | HTR2A (0.42) | HTR2AKDRTTK | |
| SCHEMBL4908416 | 0.76 | HTR2A (0.51) | HTR2AKDRDHODH | |
| SCHEMBL14281215 | 0.73 | MEN1 (0.52) | HTR2A | |
| SCHEMBL4911508 | 0.72 | HTR2A (0.43) | HTR2A | |
| SCHEMBL4906051 | 0.71 | GSK3B (0.47) | HTR2AKDR | |
| SCHEMBL4909825 | 0.71 | BCDIN3D (0.50) | HTR2AKDR | |
| SCHEMBL4909185 | 0.69 | GAA (0.43) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | claimed |
| WO-2006060762-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| WO-2006060762-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | HTR5A, HTR2A, HTR3A | HTR2A 2/4885LRRK2 1609/4885SCN5A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.